

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5029414

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ALTOS THERAPEUTICS, LLC	06/26/2018
RECEIVING PARTY DATA		
Name:	MILLENNIUM PHARMACEUTICALS, INC.	
Street Address:	40 LANDSDOWNE STREET	
City:	CAMBRIDGE	
State/Country:	MASSACHUSETTS	
Postal Code:	02139	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	14184615
CORRESPONDENCE DATA		
Fax Number:	(212)755-7306	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	858-314-1200	
Email:	wtokmakidis@jonesday.com, jdorsey@jonesday.com	
Correspondent Name:	JONES DAY	
Address Line 1:	250 VESEY STREET	
Address Line 2:	WENDY TOKMAKIDIS	
Address Line 4:	NEW YORK, NEW YORK 10281-1047	
ATTORNEY DOCKET NUMBER:	13396-058-999	
NAME OF SUBMITTER:	JESSICA L. DORSEY	
SIGNATURE:	/Jessica L. Dorsey/	
DATE SIGNED:	06/28/2018	
Total Attachments: 5		
source=13396-058-999_Assignment#page1.tif		
source=13396-058-999_Assignment#page2.tif		
source=13396-058-999_Assignment#page3.tif		
source=13396-058-999_Assignment#page4.tif		
source=13396-058-999_Assignment#page5.tif		

ASSIGNMENT AND ASSUMPTION AGREEMENT

This Assignment and Assumption Agreement, dated June 26, 2018 ("Effective Date"), is between Altos Therapeutics, LLC, a California limited liability company, ("Assignor"), and Millennium Pharmaceuticals, Inc., a Delaware corporation, ("Assignee").

Assignor is a wholly-owned subsidiary of Assignee.

Assignor desires to assign to Assignee, and Assignee desires to assume from Assignor, all of Assignor's right, title, interest in and to the assets of Assignor set forth in the attached Schedule 1 ("Assets") on the terms set forth herein.

For good, valuable, and sufficient consideration received, Assignor and Assignee agree:

1. Assignment and Assumption. As of the Effective Date, Assignor hereby assigns, conveys, and transfers to Assignee, and Assignee hereby assumes from Assignor, all of Assignor's right, title, interest in and to assets set forth in the attached Schedule 1.
2. Further Assurances. Assignor and Assignee shall each execute, acknowledge and deliver all such further documents and assurances as may be reasonably requested by the other party to implement and give effect to this agreement.
3. Counterparts. This agreement may be executed in any number of counterparts, each of which will be deemed to be an original and all of which will constitute one agreement that is binding upon the parties.
4. Governing Law. This agreement will be governed and construed in accordance with the internal laws of the state of New York, without regard to its conflicts of laws principles.

[Signature page follows]

IN WITNESS WHEREOF, the parties have entered into this Assignment and Assumption Agreement as of the Effective Date.

Assignor:

Altos Therapeutics, LLC.

By: Millennium Pharmaceuticals, Inc., as its sole Manager

By: CB

Name: Christophe Bianchi

Title: President, Global Oncology BU

Date: June 26, 2018

Assignee:

Millennium Pharmaceuticals, Inc.

By: CB

Name: Christophe Bianchi

Title: President, Global Oncology BU

Date: June 26, 2018

[Signature Page to Assignment and Assumption Agreement]

Schedule 1

Assignor's right, title and interest in and to the following assets, wherever located, as of the Effective Date:

1. Registered and non-registered copyrights, patents, including the patents set forth in the attached Exhibit A (including divisions, continuations, and continuations-in-part, renewals, extensions, reexaminations and reissues) and trademarks (including trade dress, logos, service marks, trade names, slogans and other indicia of origin) and, in each case, applications therefor, trade secrets, confidential or proprietary information, inventions, methods, processes, formulae, technology, algorithms, models, know-how and any other similar intellectual property right or intangible asset; and
2. All other assets (tangible, fixed or otherwise), including contracts, licenses, permits, regulatory filings, preclinical and clinical trial data, notes, reports, analyses, specifications, manuals, testing methods and business records.

1000

Exhibit A

Assigned Patents:

Application No.	Country	Status	Filing Date	Registration No.	Registration Date
11728491.9	Albania	Granted	17-Jun-2011	2582701	
2011268073	Australia	Granted	17-Jun-2011	2011268073	15-Oct-2015
11728491.9	Austria	Granted	17-Jun-2011	2582701	
11728491.9	Belgium	Granted	17-Jun-2011	2582701	
11728491.9	Bulgaria	Granted	17-Jun-2011	2582701	
2802188	Canada	Granted	17-Jun-2011	2802188	07-Jun-2016
201180037718.2	China	Granted	17-Jun-2011	ZL201180037718.2	09-Mar-2016
11728491.9	Croatia	Granted	17-Jun-2011	2582701	
11728491.9	Cyprus	Granted	17-Jun-2011	2582701	
11728491.9	Czechia	Granted	17-Jun-2011	2582701	
11728491.9	Denmark	Granted	17-Jun-2011	2582701	
11728491.9	Estonia	Granted	17-Jun-2011	2582701	
11728491.9	European Patent	Granted	17-Jun-2011	2582701	
16192596.1	European Patent	Pending	17-Jun-2011		
11728491.9	Finland	Granted	17-Jun-2011	2582701	
11728491.9	France	Granted	17-Jun-2011	2582701	
11728491.9	Germany	Granted	17-Jun-2011	2582701	
11728491.9	Greece	Granted	17-Jun-2011	2582701	
17108890.5	Hong Kong	Pending	17-Jun-2011		
11728491.9	Hungary	Granted	17-Jun-2011	2582701	
11728491.9	Iceland	Granted	17-Jun-2011	2582701	
41/CHENP/2013	India	Pending	17-Jun-2011		
11728491.9	Ireland	Granted	17-Jun-2011	2582701	
250606	Israel	Pending	17-Jun-2011		
257429	Israel	Pending	17-Jun-2011		
223515	Israel	Granted	17-Jun-2011	223515	01-Jul-2017
11728491.9	Italy	Granted	17-Jun-2011	2582701	
2013-515569	Japan	Granted	17-Jun-2011	5860457	25-Dec-2015
10-2013-7000599	Korea, Republic	Granted	17-Jun-2011	10-1601383	02-Mar-2016
11728491.9	Latvia	Granted	17-Jun-2011	2582701	
11728491.9	Lithuania	Granted	17-Jun-2011	2582701	
11728491.9	Luxembourg	Granted	17-Jun-2011	2582701	
11728491.9	Macedonia, The	Granted	17-Jun-2011	2582701	
11728491.9	Malta	Granted	17-Jun-2011	2582701	
MX/a/2012/014470	Mexico	Granted	17-Jun-2011	323020	19-Aug-2014
MX/a/2014/009737	Mexico	Allowed	17-Jun-2011		
MX/a/2017/013063	Mexico	Pending	17-Jun-2011		
11728491.9	Monaco	Granted	17-Jun-2011	2582701	
11728491.9	Netherlands	Granted	17-Jun-2011	2582701	
605431	New Zealand	Granted	17-Jun-2011	605431	29-Sep-2015
11728491.9	Norway	Granted	17-Jun-2011	2582701	
PCT/US2011/40983	PCT Application	National Phase	17-Jun-2011		
11728491.9	Poland	Granted	17-Jun-2011	2582701	
11728491.9	Portugal	Granted	17-Jun-2011	2582701	
11728491.9	Romania	Granted	17-Jun-2011	2582701	
11728491.9	San Marino	Granted	17-Jun-2011	2582701	
11728491.9	Serbia	Granted	17-Jun-2011	2582701	
11728491.9	Slovakia	Granted	17-Jun-2011	2582701	
11728491.9	Slovenia	Granted	17-Jun-2011	2582701	
11728491.9	Spain	Granted	17-Jun-2011	2582701	
11728491.9	Sweden	Granted	17-Jun-2011	2582701	
11728491.9	Switzerland	Granted	17-Jun-2011	2582701	
11728491.9	Turkey	Granted	17-Jun-2011	2582701	
11728491.9	United Kingdom	Granted	17-Jun-2011	2582701	
61/356096	United States	Expired	18-Jun-2010		
13/163592	United States	Granted	17-Jun-2011	8691836	08-Apr-2014
14/184615	United States	Granted	19-Feb-2014	9156840	13-Oct-2015

STATE OF Massachusetts

COUNTY OF Middlesex

)
) ss.:
)

On this 26th day of June, 2018, before me, the undersigned Notary Public, **Christophe Bianchi** personally appeared, proved to me through satisfactory evidence of identification, which was drivers license, to be the person whose name is signed on the preceding or attached document, and acknowledged to me that he signed it voluntarily for its stated purpose as **President, Global Oncology BU for Assignor, Altos Therapeutics, LLC**, and as **President, Global Oncology BU for Assignee, MILLENNIUM PHARMACEUTICALS, INC.**

WITNESS my hand and notarial seal, this 26th day of June, 2018.

Daphne S. Howe
Notary Public

